0001628280-26-032093
SEC filingGinkgo Bioworks reported Q1 2026 revenue of $19 million, down 49% year-over-year, GAAP net loss from continuing operations of $(76) million, and cash balance of $373 million after Biosecurity divestiture.
Ginkgo Bioworks announced Q1 2026 financial results reflecting the impact of its completed Biosecurity divestiture on April 3, 2026, with prior periods recast to present continuing operations as a single reporting segment. Revenue declined 49% to $19 million from $38 million in the prior year quarter, primarily due to ongoing program rationalization amid restructuring activities. Excluding a $7 million non-cash deferred revenue release in Q1 2025, the decline was 37% from $31 million, underscoring the effects of customer program adjustments. Despite revenue contraction, GAAP net loss from continuing operations improved to $(76) million from $(83) million, signaling some cost discipline. Adjusted EBITDA loss narrowed slightly to $(42) million from $(44) million. Cash position remained solid at $373 million as of March 31, 2026. Management reaffirmed full-year 2026 total cash burn guidance of $(150)-(125) million, providing visibility into liquidity management. CEO Jason Kelly highlighted the scaling of Nebula, the world's largest autonomous lab targeting a doubling in size this year, positioning Ginkgo to lead the shift from manual lab work to 24/7 autonomous infrastructure integrated with AI models. Business highlights emphasized revenue-generating Cloud Lab, Datapoints, and Solutions offerings, with partnerships like ProQR and Amazon, reinforcing strategic focus on platform expansion amid restructuring.